SeQure Dx provides analytical tools that evaluate on-target specificity and off-target risks in CRISPR gene editing therapies, ensuring safety throughout the development process. By delivering precise safety data, the company addresses concerns about unintended genomic alterations that could impact patient outcomes and regulatory compliance.
Funding
$22.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MGFounders
Product
Problem
CRISPR gene editing therapies carry the risk of unintended off-target effects, potentially leading to life-altering consequences for patients. Comprehensive risk assessment is crucial to inform regulatory filings, support clinical decision-making, and conduct post-market surveillance.
Solution
SeQure Dx provides analytical tools and services for comprehensive on- and off-target assessment of gene editing therapies, ensuring patient safety and regulatory compliance. Their portfolio of assays supports every phase of therapeutic development, from initial research to clinical trials and commercialization. By offering screening, nomination, and confirmation assays, SeQure Dx enables developers to make data-driven decisions, reduce costs, and accelerate the path to safer, more effective therapies. The company's services are editor-agnostic and scalable, providing both individual and population-level insights.
Target Audience
SeQure Dx serves biopharmaceutical companies, translational centers, and academic institutions involved in cell and gene therapy development, drug discovery, and gene editing.
Features
- Guide Profiler™ and Guide Select™ assays for early-stage screening of guide RNAs
- ONE-seq, DEUX-seq™, and GUIDE-seq™ assays for nomination of potential off-target sites
- Amplicon-seq™ and SAFER Detection™ assays for confirmation of on- and off-target events
- Proprietary analytical tools delivering unparalleled sensitivity and scalability
- Services align with FDA guidance for gene-edited therapies
- Support for both viral and non-viral editing platforms